The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study
- 25 October 2011
- journal article
- clinical trial
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 47 (3) , 313-320
Abstract
Treatment with terlipressin and albumin has been reported recently to be effective in improving renal function in the treatment of cirrhotic patients with hepatorenal syndrome (HRS). The aim of this prospective, multicenter study was to investigate the efficacy and safety of treatment with terlipressin and albumin in Japanese cirrhotic patients with type 1 HRS.Keywords
This publication has 19 references indexed in Scilit:
- Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta‐analysis of randomized controlled trialsJournal of Gastroenterology and Hepatology, 2010
- A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal SyndromeGastroenterology, 2008
- Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal SyndromeDigestive Diseases and Sciences, 2007
- Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndromeJournal of Hepatology, 2007
- The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyondHepatology, 2006
- Hepatorenal syndromeThe Lancet, 2003
- Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trialJournal of Gastroenterology and Hepatology, 2003
- Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysisJournal of Gastroenterology and Hepatology, 2002
- Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: A retrospective multicenter studyGastroenterology, 2002
- Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.2001